Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-028-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- Toxicokinetic assessment of the substance based on the available data
- Type of information:
- other: expert statement
- Adequacy of study:
- key study
- Study period:
- Not applicable
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: since this is a theoretical assessment, the Klimisch value cannot be 1.
- Objective of study:
- other: Toxicokinetic assessment of the substance based on the available data
- Qualifier:
- according to guideline
- Guideline:
- other: Guidance for the implementation of REACH. Guidance on information requirements and chemical safety assessment. Chapter R.7c: Endpoint specific guidance. European Chemical Agency
- Version / remarks:
- Version 2.0; November 2014
- Deviations:
- no
- GLP compliance:
- no
- Conclusions:
- For risk assessment purposes, 10% is used for oral and dermal absorption and 50% is used for inhalation absorption.
Reference
TOXICOKINETIC ASSESSMENT
A substance can enter the body via the gastrointestinal tract, the lungs, or the skin, depending on the route of exposure.
After oral administration, in general, a compound needs to be dissolved before it can be taken up from the gastro-intestinal tract. L 125 PLUS is considered to be insoluble in water, therefore passive diffusion (passage of small water-soluble molecules through aqueous pores or carriage of such molecules across membranes with the bulk passage of water) is expected to be low. Due to its insolubility in water and its limited ability to penetrate biomembranes related to its size, oral absorption is considered to be limited. For risk assessment purposes oral absorption of L 125 PLUS is set at 10%. The oral toxicity data do not provide reason to deviate from the proposed oral absorption factor.
Once absorbed, wide distribution of L 125 PLUS throughout the body is not expected based on its insolubility in water and absorbed L 125 PLUS is not expected to bio-accumulate significantly in the body upon exposure.
L 125 PLUS particles are relatively small with more than 85% of the particle smaller than 10 μm. In general, particles with aerodynamic diameters below 100 μm have the potential to be inhaled. Particles with aerodynamic diameters below 50 μm may reach the thoracic region and those below 15 μm can enter the alveolar region of the respiratory tract in humans. This indicates that during exposure by inhalation to L 125 PLUS, the substance can reach the nasopharyncheal region and subsequently the tracheo/bronchial/pulmonary region. Once L 125 PLUS reaches the lung tissue, it will not dissolve within the mucus lining of the respiratory tract due to its insolubility in water. L 125 PLUS deposited in the tracheobronchial region is expected to be cleared from the lungs by the mucocilliary mechanism and swallowed. However, a small amount may be engulfed by alveolar macrophages, although its particle size does not favour phagocytosis which is more likely to occur with smaller particles (around 1 μm). In case of uptake, macrophages will then either translocate particles to the ciliated airways or carry particles into the pulmonary interstitium and lymphoid tissues. Based on the above data, for risk assessment purposes the inhalation absorption of L 125 PLUS is set at 50%.
L 125 PLUS is a powdery solid. Given the fact that L 125 PLUS is insoluble in water, it is not expected to be dissolved in the moisture of the skin and uptake will therefore be limited, and consequently dermal absorption is likely to be low. Furthermore, its inorganic nature is not indicative for fast uptake. According to the criteria given in the REACH Guidance, 10% dermal absorption will be considered in case MW >500 and log Pow <-1 or >4, otherwise 100% dermal absorption should be used. As no partition coefficient is available, due to the water insoluble properties of the substance, L 125 PLUS cannot be tested against the criteria for limited dermal absorption. It is however generally accepted that dermal absorption is equal or lower compared to oral absorption for non-irritating/non-corrosive substances, and therefore a dermal absorption of 10% is considered to be more appropriate. Therefore, for risk assessment purposes dermal absorption is set at 10%.
Description of key information
For risk assessment purposes, 10% is used for oral and dermal absorption and 50% is used for inhalation absorption.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 10
- Absorption rate - dermal (%):
- 10
- Absorption rate - inhalation (%):
- 50
Additional information
A substance can enter the body via the gastrointestinal tract, the lungs, or the skin, depending on the route of exposure. After oral administration, in general, a compound needs to be dissolved before it can be taken up from the gastro-intestinal tract. L 125 PLUS is considered to be insoluble in water, therefore passive diffusion (passage of small water-soluble molecules through aqueous pores or carriage of such molecules across membranes with the bulk passage of water) is expected to be low. Due to its insolubility in water and its limited ability to penetrate biomembranes related to its size, oral absorption is considered to be limited. For risk assessment purposes oral absorption of L 125 PLUS is set at 10%. The oral toxicity data do not provide reason to deviate from the proposed oral absorption factor.
Once absorbed, wide distribution of L 125 PLUS throughout the body is not expected based on its insolubility in water and absorbed L 125 PLUS is not expected to bio-accumulate significantly in the body upon exposure.
L 125 PLUS particles are relatively small with more than 85% of the particle smaller than 10 μm. In general, particles with aerodynamic diameters below 100 μm have the potential to be inhaled. Particles with aerodynamic diameters below 50 μm may reach the thoracic region and those below 15 μm can enter the alveolar region of the respiratory tract in humans. This indicates that during exposure by inhalation to L 125 PLUS, the substance can reach the nasopharyncheal region and subsequently the tracheo/bronchial/pulmonary region. Once L 125 PLUS reaches the lung tissue, it will not dissolve within the mucus lining of the respiratory tract due to its insolubility in water. L 125 PLUS deposited in the tracheobronchial region is expected to be cleared from the lungs by the mucocilliary mechanism and swallowed. However, a small amount may be engulfed by alveolar macrophages, although its particle size does not favour phagocytosis which is more likely to occur with smaller particles (around 1 μm). In case of uptake, macrophages will then either translocate particles to the ciliated airways or carry particles into the pulmonary interstitium and lymphoid tissues. Based on the above data, for risk assessment purposes the inhalation absorption of L 125 PLUS is set at 50%.
L 125 PLUS is a powdery solid. Given the fact that L 125 PLUS is insoluble in water, it is not expected to be dissolved in the moisture of the skin and uptake will therefore be limited, and consequently dermal absorption is likely to be low. Furthermore, its inorganic nature is not indicative for fast uptake. According to the criteria given in the REACH Guidance, 10% dermal absorption will be considered in case MW >500 and log Pow <-1 or >4, otherwise 100% dermal absorption should be used. As no partition coefficient is available, due to the water insoluble properties of the substance, L 125 PLUS cannot be tested against the criteria for limited dermal absorption. It is however generally accepted that dermal absorption is equal or lower compared to oral absorption for non-irritating/non-corrosive substances, and therefore a dermal absorption of 10% is considered to be more appropriate. Therefore, for risk assessment purposes dermal absorption is set at 10%.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.